Riskpilot← Back to searchSign inGet full accessAkuru Pharma AB
ABIn liquidationOrg 5590587423Research and experimental development on biotechnology · NACE 7211Est. 20160 employees
Revenue 2019
SEK 0
EBITDA margin
—
-110% vs 2018
Equity ratio
87.4%
Financial strength
Net profit 2019
SEK -105K
-450% vs 2018
| Revenue | SEK 0 | — |
| EBITDA | SEK -13K | -110% |
| Net profit | SEK -105K | -450% |
| Total assets | SEK 190K | -36% |
| Equity | SEK 166K | -39% |
| Employees | 0 | — |
Legal name
Akuru Pharma AB
Org number
5590587423
Legal form
Aktiebolag
NACE code
7211 · Research and experimental development on biotechnology
Founded
14 april 2016
Share capital
SEK 0
Employees
0
VAT registered
No
Audit selected
No
Last report
2019-12-31
Financial year
January – December
Company purpose
Bolaget ska bedriva verksamhet inom biomedicinsk diagnostik och utveckling av nya terapier för behandling av cancer. Verksamheten omfattar utveckling, licensiering, marknadsföring, distribution och försäljning av biomedicinsk diagnostik och terapi för cancerbehandling och biovetenskapliga metoder, teknik, reagenser, produkter och laboratorietjänster. En särskild inriktning på företaget är detektion och behandling av njurcancer, samt därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — |
| EBITDA | −3 | −142 | 125 | −13 |
| Depreciation & amort. | −0 | −0 | −95 | −92 |
| EBIT | −3 | −142 | 30 | −105 |
| Net financials | — | — | — | — |
| Profit before tax | −3 | −142 | 30 | −105 |
| Tax | −0 | −0 | −0 | −0 |
| Net profit | −3 | −142 | 30 | −105 |
| Item | 2016 | 2017 | 2018 | 2019 |
|---|---|---|---|---|
| Total assets | 805 | 1 287 | 298 | 190 |
| Equity | 344 | 226 | 271 | 166 |
| Long-term debt | 0 | 0 | 0 | 0 |
| Short-term debt | 461 | 1 060 | 27 | 23 |
| Total debt | 461 | 1 060 | 27 | 23 |
EBITDA margin
-1300000.0%
This company
15.8%
Market median
-8227948% vs market
20162019
Equity ratio
87.4%
This company
38.2%
Market median
+129% vs market
20162019
Return on equity
-63.3%
This company
18.4%
Market median
-444% vs market
20162019
Net profit margin
-10500000.0%
This company
8.1%
Market median
-129629730% vs market
20162019
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20162019
Debt / equity
0.14×
This company
0.62×
Market median
+77% vs market
20162019
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-04-01 – 2016-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
O Liquidator | Liquidator | 2021 | — | — |
MS Chief Auditor | Chief Auditor | 2020 | — | — |
UC Liquidator | Liquidator | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Chairman | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Akuru Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Okänt | Liquidator | 0 companies |
| Maria Sofia Ekelund | Chief Auditor | 0 companies |
| Ulf Christer Yxklinten | Liquidator | 0 companies |
| Karin Marie Christine Widstrand | Board of Directors | 0 companies |
| Håkan Johannes Axelson | Chairman | 0 companies |
| Lena Birgitta Marie Gustafsson | Board of Directors | 0 companies |
| Jennifer Irene Hansson | Board of Directors | 0 companies |